Cargando…
Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with a poor prognosis. Human papilloma virus (HPV) infection is associated with 20% HNSCC, and 50% of oropharyngeal carcinoma. HPV16 type is detected in 90% of all HPV+ HNSCC. Recently we suggeste...
Autores principales: | Harris, Matthew, Wang, Xing Guo, Jiang, Zewei, Goldberg, Gary L, Casadevall, Arturo, Dadachova, Ekaterina |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046925/ https://www.ncbi.nlm.nih.gov/pubmed/21314983 http://dx.doi.org/10.1186/1758-3284-3-9 |
Ejemplares similares
-
Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC)
por: Bteich, Yara T, et al.
Publicado: (2022) -
Differential expression profiling of head and neck squamous cell carcinoma (HNSCC)
por: Lemaire, F, et al.
Publicado: (2003) -
Comprehensive Genomic Review of TCGA Head and Neck Squamous Cell Carcinomas (HNSCC)
por: Pérez Sayáns, Mario, et al.
Publicado: (2019) -
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
por: Dadachova, Ekaterina, et al.
Publicado: (2011) -
MUC1 confers radioresistance in head and neck squamous cell carcinoma (HNSCC) cells
por: Huang, Tian-qiao, et al.
Publicado: (2020)